Created in 2005, the European Technology Platform on Nanomedicine is an initiative led by Industry and set up together with the European Commission to address the applications of nanotechnology to achieve breakthroughs in healthcare. The ETPN is structuring and federating the European Nanomedicine community and leading the communication toward the European Commission and the European Members States.
The ETPN contributed to set up numerous European funded projects providing a first impression of economic environment and the structural requirements for an efficient translation of R&D results into innovative nanomedicine.
ENATRANS has been built to help the translation of innovative projects related to Nanomedicine to successfully go through the different stages of development from the idea to the patients and also improve global knowledge on Nanomedicine.
The key corner stone of ENATRANS is the Translation Advisory Board (TAB) a new instrument to provide free of charge advice and support ambitious European Nanomedicine projects. First-in-class recognized experts from industry will deliver concrete and invaluable advice to drive selected Nanomedicine projects into innovative products for healthcare.
ENATRANS is led by a consortium of 7 partners belonging to the European Technology Platform for Nanomedicine (ETPN): CEA-LETI (Grenoble, France), Nanobiotix SA (Paris, France), Gesellschaft für Bioanalytik Muenster e.V. (Muenster, Germany), Tel-Aviv University (Tel-Aviv, Israel), Fondazione Don Carlo Gnocchi ONLUS (Milan, Italy), TecMinho (Braga, Portugal) and VDI/VDE-IT (coordinator) (Berlin, Germany).
Nano World Cancer Day © 2016